
|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach
by Karl Bayer, Monika Cserjan-Puschmann, Reingard Grabherr, Gerald Striedner, and Franz Clementschitsch, Institute of Applied Microbiology, Vienna, Austria A new strategy for controlling recombinant gene expression improves efficiency, maximizes host vector exploitation, reduces costs, improves product consistency, and accelerates product development. Continuous feeds of limited amounts of inducer proportional to biomass growth grant optimal control over the ratio between gene expression and host cell metabolism, providing stable, prolonged recombinant protein production.
Advertisement
Articles in this issue
over 24 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveover 24 years ago
Knowledge Management: The Four Pillars of Successover 24 years ago
Inside Washington: One Hundred Years of Biotech Regulationover 24 years ago
Guest Editorial: Supreme Court Rules on FestoAdvertisement
Related to this article

In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.

As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.

Lilly’s retatrutide more than doubles Ozempic’s weight loss in a phase 3 head-to-head trial, Iovance’s lifileucel reaches a 52% response rate in a biomarker-selected lung cancer subgroup, and FDA issues draft guidance on licensing individualized genome editing products.

DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.

Updated phase 2 IOV-LUN-202 data show Iovance’s TIL cell therapy lifileucel produced a 24.6% response rate in previously treated non-squamous metastatic NSCLC, rising to 52.0% in KRAS and HER2 wild-type patients, as the company launches a biomarker-enriched registrational cohort.

The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.

In the 80-week phase 3 TRANSCEND-T2D-2 trial in adults with type 2 diabetes, Eli Lilly’s GIP/GLP-1/glucagon triple agonist retatrutide lowered A1C by 2.2% and body weight by up to 20.9%, compared with 1.8% and 9.4% with Ozempic 2 mg.
Advertisement
Advertisement
Trending on BioPharm International
1
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
2
Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial
3
AbbVie Files BLA With FDA for Etentamig in Relapsed/Refractory Myeloma
4
Astellas Takes Option on Audax IL-12 Antibody-Cytokine Fusion DAX-044
5
